Alembic Pharmaceuticals Ltd (APLLTD) Q1FY26 Concall Summary - Jun-2025 Qtr
Performance Overview
- Alembic Pharmaceuticals reported a 10% YoY growth in total revenue, reaching Rs. 1,711 crores in Q1 FY26.
- Growth was observed across various business segments, even with pricing pressures in the US Generics and API segments.
- Gross margin improved to 76.2% compared to 74.8% in Q1 FY25, attributed to product mix and cost optimization initiatives.
- EBITDA before R&D expenses saw a 23% YoY increase, reaching Rs. 424 crores, driven by revenue growth, improved gross margins, and better facility utilization.
- R&D expenses rose by 26% YoY to Rs. 145 crores, aligning with the full-year guidance of Rs. 600-650 crores.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.